866-997-4948(US-Canada Toll Free)

Global Molecular Diagnostics 2010-2015: Deal trends, players, financials and forecasts

Published By :

Current Partnering

Published Date : Sep 2015

Category :

Molecular Diagnostics

No. of Pages : 512 Pages

The Global Molecular Diagnostics 2010-2015 report provides a detailed understanding and analysis of how and why companies enter molecular diagnostics partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Table of Content

Executive Summary
 
Chapter 1 – Introduction

 
Chapter 2 – Trends in molecular diagnostics dealmaking
2.1. Introduction
2.2. Molecular diagnostics partnering over the years
2.3. Molecular diagnostics partnering by industry type
2.4. Molecular diagnostics partnering by deal type
2.5. Molecular diagnostics partnering by disease type
2.6. Molecular diagnostics partnering by stage of development
 
Chapter 3 – Average financial deal terms for molecular diagnostics partnering
3.1. Introduction
3.2. Disclosed financials terms for molecular diagnostics partnering
3.2.1 Molecular diagnostics partnering headline values
3.2.2 Molecular diagnostics upfront payments
3.2.3 Molecular diagnostics milestone payments
3.2.4 Molecular diagnostics royalty rates
 
Chapter 4 – Leading molecular diagnostics deals
4.1. Introduction
4.2. Top molecular diagnostics deals by value
4.3. Most active in molecular diagnostics partnering
4.4. Big pharma molecular diagnostics dealmaking activity
4.5. Big pharma molecular diagnostics partnering company profiles
 
Chapter 5 – Molecular diagnostics partnering contracts directory
5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By stage of development
5.5. By therapy area
 
Chapter 6 – Molecular diagnostics dealmaking directory
6.1. Introduction
6.2. Deals by molecular diagnostics type, includes theranostics
 
Chapter 7 – Future trends and companies in molecular diagnostics deal making
7.1. Introduction
7.2. Emerging companies to watch in 2015
7.3. Emerging companies dealmaking in 2010-2015
7.4. Emerging company financings in 2010-2015
7.5 Conclusion

Appendices
Introduction
Appendix 1 – Directory of molecular diagnostics deals by company A-Z 2010 to 2015
Appendix 2 – Directory of molecular diagnostics deals by stage of development 2010 to 2015
Appendix 3 – Directory of molecular diagnostics deals by deal type 2010 to 2015
Appendix 4 – Directory of molecular diagnostics deals by therapy area 2010 to 2015
Appendix 5 – Molecular diagnostics partnering resource center
Online molecular diagnostics partnering
The anatomy of molecular diagnostics partnering
The anatomy of a molecular diagnostics deal
Molecular Diagnostics partnering events
Further reading on molecular diagnostics dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from CurrentPartnering

List of Table

NA

List of Chart

Figure 1: Molecular diagnostics partnering since 2010
Figure 2: Molecular diagnostics partnering by industry sector since 2010
Figure 3: Molecular diagnostics partnering by deal type since 2010
Figure 4: Molecular diagnostics partnering by disease type since 2010
Figure 5: Molecular diagnostics partnering by stage of development since 2010
Figure 6: Molecular diagnostics deals with a headline value by year- 2015
Figure 7: Molecular diagnostics deals with a headline value by year- 2014
Figure 8: Molecular diagnostics deals with a headline value by year- 2013
Figure 9: Molecular diagnostics deals with a headline value by year- 2012
Figure 10: Molecular diagnostics deals with a headline value by year- 2011
Figure 11: Molecular diagnostics deals with a headline value by year- 2010
Figure 12: Molecular diagnostics deals with an upfront value by year- 2015
Figure 13: Molecular diagnostics deals with an upfront value by year- 2014
Figure 14: Molecular diagnostics deals with an upfront value by year- 2013
Figure 15: Molecular diagnostics deals with an upfront value by year- 2012
Figure 16: Molecular diagnostics deals with an upfront value by year- 2011
Figure 17: Molecular diagnostics deals with an upfront value by year- 2010
Figure 18: Molecular diagnostics deals with a milestone value by year- 2015
Figure 19: Molecular diagnostics deals with a milestone value by year- 2014
Figure 20: Molecular diagnostics deals with a milestone value by year- 2013
Figure 21: Molecular diagnostics deals with a milestone value by year- 2012
Figure 22: Molecular diagnostics deals with a milestone value by year- 2011
Figure 23: Molecular diagnostics deals with a milestone value by year- 2010
Figure 24: Molecular diagnostics deals with a royalty rate value by year- 2015
Figure 25: Molecular diagnostics deals with a royalty rate value by year- 2014
Figure 26: Molecular diagnostics deals with a royalty rate value by year- 2013
Figure 27: Molecular diagnostics deals with a royalty rate value by year- 2012
Figure 28: Molecular diagnostics deals with a royalty rate value by year- 2011
Figure 29: Molecular diagnostics deals with a royalty rate value by year- 2010
Figure 30: Top molecular diagnostics deals by value since 2010
Figure 31: Active molecular diagnostics dealmaking activity– 2010 to 2015
Figure 32: Big pharma – top 50 – Molecular diagnostics deals 2010 to 2015
Figure 33: Big pharma molecular diagnostics deal frequency – 2010 to 2015
Figure 34: Online partnering resources
Figure 35: Components of the typical molecular diagnostics deal structure
Figure 36: Forthcoming partnering events

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *